published meta-analysis   sensitivity analysis   studies

Immunostimulants drugs in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias Emergency room visit or hospitalizationdetailed resultsCov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 0.12 [0.01; 2.35] 0.12[0.01; 2.35]Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 202110%1,505NAnot evaluable deathsdetailed resultsBLAZE-2 US (Cohen), 2021 0.83 [0.25; 2.73] Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 1.00 [0.14; 7.08] 0.87[0.31; 2.41]BLAZE-2 US (Cohen), 2021, Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 202120%3,583moderatenot evaluable hospitalizationdetailed resultsPROVENT, 2022 0.04 [0.00; 0.63] 0.04[0.00; 0.63]PROVENT, 202210%4,685NAnot evaluable symptomatic Covid-19detailed resultsCov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 0.17 [0.09; 0.33] PROVENT, 2022 0.23 [0.10; 0.54] 0.19[0.12; 0.33]Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021, PROVENT, 202220%6,577moderatenot evaluable infection (PCR positive symptomatic or not)detailed resultsBLAZE-2 US (Cohen), 2021 0.43 [0.28; 0.67] 0.43[0.28; 0.67]BLAZE-2 US (Cohen), 202110%961NAnot evaluable severe COVID-19 occurrencedetailed resultsPROVENT, 2022 0.25 [0.01; 7.50] 0.25[0.01; 7.50]PROVENT, 202210%5,172NAnot evaluable serious adverse eventsdetailed resultsCov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 2.97 [1.75; 5.03] 2.97[1.75; 5.03]Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 202110%2,617NAnot evaluable adverse eventsdetailed resultsBLAZE-2 US (Cohen), 2021 2.02 [1.54; 2.64] Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 0.62 [0.52; 0.74] 1.11[0.35; 3.53]BLAZE-2 US (Cohen), 2021, Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021298%3,792moderatenot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:36 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567 - roots T: 290